ChartMill assigns a Buy % Consensus number of 86% to BBNX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-29 | Stifel | Reiterate | Buy -> Buy |
| 2025-10-29 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-29 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-10-21 | Stifel | Reiterate | Buy |
| 2025-10-01 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2025-09-22 | Truist Securities | Maintains | Buy -> Buy |
| 2025-07-30 | Truist Securities | Maintains | Buy -> Buy |
| 2025-07-30 | Baird | Maintains | Neutral -> Neutral |
| 2025-06-16 | Truist Securities | Initiate | Buy |
| 2025-05-30 | Wolfe Research | Initiate | Outperform |
| 2025-05-30 | Goldman Sachs | Initiate | Neutral |
| 2025-02-24 | Leerink Partners | Initiate | Outperform |
| 2025-02-24 | Lake Street | Initiate | Buy |
| 2025-02-24 | Stifel | Initiate | Buy |
| 2025-02-24 | Piper Sandler | Initiate | Overweight |
| 2025-02-20 | Ladenburg Thalmann | Initiate | Buy |
| 2025-02-20 | Baird | Initiate | Neutral |
16 analysts have analysed BBNX and the average price target is 31.93 USD. This implies a price increase of 8.67% is expected in the next year compared to the current price of 29.38.
The consensus rating for BETA BIONICS INC (BBNX) is 86.25 / 100 . This indicates that analysts generally have a positive outlook on the stock.